Status: Recruiting
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Participants needed: 150
Trial details
Age: 18-110Biological sex: FemaleType: ObservationalSponsor: Radboud University Medical CenterUpdated: Jan 18, 2023Locations: 1Duration: 2 Years
Eligibility criteria
Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer [+3]
Adjuvant hormonal therapy started following complete resection of endometrial ca... [+2]